The 4 mm threshold is critical as it determines periodontal disease stability at non-bleeding sites following successful periodontal therapy.1,3 However, it is important to note that a higher probing depth of 5 mm or 6 mm in the absence of bleeding may not necessarily represent active disease, in particular soon after periodontal treatment.
Activity was noted, with a partial response in one patient and prolonged disease stability for >12 cycles in three patients.The combination of enzastaurin 500 mg daily and erlotinib 150 mg daily is well tolerated and does not alter the pharmacokinetics of the individual drugs, with clinical activity seen.
Patients with relapses were tapered more quickly (8.4 vs. 62.4 months).Tapering MMF appears safe after years of disease stability.
Survival is the primary measure of treatment efficacy, but other end points, such as quality of life and disease stability, should also be considered in advanced disease.
Palliative or non-curative treatment intent was defined as patients with no further active treatment options available, but those that could be on phase 1 trials or be receiving treatment to control or maintain disease stability but without curative intent.
Initial evolution of chorioretinal lesions over a 4-year period to disease activity (fourth frame OS) then quiescent on treatment in 2010: disease stability in 2007, 2008, 2009, 2010 (active disease), and 2011 (quiescent disease).
Results from a mid-stage clinical trial showed that the use of Erbitux along with a chemotherapy regimen known as Folfox-4 had a 10% response rate in colorectal cancer patients whose disease had spread, a 71% partial response rate, and a rate of 17% of patients achieving disease stability.
This is the period we have associated with disease stability, similar to that which is seen in patients as it is roughly equivalent to the increase in tumor size (20% increase in long axis by RECIST criteria) that would classify a patient as having progressive disease (and therefore, treatment resistance) while receiving such therapy.
Disease stability was demonstrated in 54.3% of men.
This principle holds true under the assumptions of disease stability.
Preliminary results after 12 months of follow-up suggested that disease stability was maintained after switching.
